# BioNTech

Source: https://onco.cc/companies/biontech/  
OnCo record `biontech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

From COVID vaccine to a broad oncology pipeline: personalised vaccines, ADCs from China, and a PD-L1×VEGF bispecific sold to BMS for $11B.

## Summary

BioNTech, based in Mainz and listed as BNTX, moved from its COVID vaccine into a broad oncology pipeline of personalised vaccines, antibody-drug conjugates licensed from China, and a PD-L1 by VEGF bispecific sold to Bristol Myers Squibb for 11 billion dollars. Its programmes include autogene cevumeran with Genentech, trastuzumab pamirtecan, or BNT323, from DualityBio, pumitamig, or BNT327, with BMS, BNT113 against HPV16 and the Claudin 6 CAR-T BNT211. OnCo links it to pancreatic ductal adenocarcinoma through Rojas 2023, in which a personalised mRNA vaccine trained T cells against each patient's cancer, to Claudin 6 as a target, to CureVac and to the University Cancer Center Mainz. Cold tumours and the immunosuppressive microenvironment are the bottleneck its vaccines address. Autogene cevumeran has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Mainz
- Type: biotech
- Website: https://www.biontech.com
- Ticker: BNTX

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/BioNTech
- Official website: https://www.biontech.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Autogene cevumeran](https://onco.cc/drugs/autogene-cevumeran/), [BNT113](https://onco.cc/drugs/bnt113/), [BNT324](https://onco.cc/drugs/bnt324/), [PM8002](https://onco.cc/drugs/pm8002/), [Trastuzumab pamirtecan](https://onco.cc/drugs/trastuzumab-pamirtecan/)
- companies: [CureVac](https://onco.cc/companies/curevac/)
- trials: [A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer](https://onco.cc/trials/nct06340568/), [A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer](https://onco.cc/trials/nct06827236/), [A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer](https://onco.cc/trials/nct06892548/), [A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3](https://onco.cc/trials/nct07079631/), [A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors](https://onco.cc/trials/nct07070232/), [A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1](https://onco.cc/trials/nct04534205/), [A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N](https://onco.cc/trials/nct07255404/), [A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma](https://onco.cc/trials/nct07297212/), [A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ](https://onco.cc/trials/nct07111520/), [A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9](https://onco.cc/trials/nct07186842/), [A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors](https://onco.cc/trials/nct07147348/), [A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05150691/), [A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05914116/), [A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer](https://onco.cc/trials/nct04486378/), [A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct07365995/), [A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC](https://onco.cc/trials/nct05844150/), [A Study of PM8002 in Combination With Chemotherapy in Patients With NEN](https://onco.cc/trials/nct05879055/), [A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC](https://onco.cc/trials/nct05879068/), [A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC](https://onco.cc/trials/nct05918133/), [A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC](https://onco.cc/trials/nct05968326/), [A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)](https://onco.cc/trials/nct07221149/), [Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)](https://onco.cc/trials/autogene-cevumeran-phase-1/), [DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06953089/), [Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors](https://onco.cc/trials/nct07455734/), [First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05438329/), [PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct07133750/), [PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer](https://onco.cc/trials/nct06616532/), [PM8002 in the Treatment of Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05918445/), [PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC](https://onco.cc/trials/nct06419621/), [ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer](https://onco.cc/trials/nct07173751/), [Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer](https://onco.cc/trials/nct06712355/), [Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors](https://onco.cc/trials/nct06750185/), [Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy](https://onco.cc/trials/nct06449222/), [Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che](https://onco.cc/trials/nct06841055/), [Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer](https://onco.cc/trials/nct06712316/), [Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy](https://onco.cc/trials/nct06449209/)
- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- key papers: [RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer](https://onco.cc/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/), [Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer](https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- technologies: [mRNA and lipid nanoparticle manufacturing](https://onco.cc/technologies/mrna-lnp-manufacturing/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/), [Self-amplifying and circular RNA therapeutics](https://onco.cc/technologies/self-amplifying-rna/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/)
- ideas: [Personalised cancer vaccines at commodity cost through fully automated manufacturing](https://onco.cc/ideas/idea-moon-neoantigen-vaccines-at-scale/), [Personalised vaccines given only when the blood test turns positive](https://onco.cc/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/), [Vaccines aimed only at mutations shared by every tumour cell](https://onco.cc/ideas/idea-bio1-clonal-neoantigen-vaccines/)
- targets: [Claudin 6](https://onco.cc/targets/cldn6/)
- institutions: [University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz](https://onco.cc/institutions/uct-mainz/)

---
JSON: https://onco.cc/api/v1/entities/biontech.json